Home

Cover Story

Table of Contents

E-Newsletter

Article Archive

Editorial Calendar

Datebook

Writers' Guidelines

Orgs/Links

Opinion Polls

Reprints

Forum

Search

May 9 -Drug-Releasing Stent Improves Coronary Artery Disease Outcomes in Study

A new drug-releasing stent produced promising results compared to a current drug-releasing stent treatment, according to a study in the April 23/30 issue of The Journal of the American Medical Association. Angioplasty patients who received stents releasing the drug everolimus experienced a lower rate of renarrowing of the coronary arteries and a significantly reduced risk of major cardiac events compared to patients who received the widely-used paclitaxel-releasing stents.

Stents releasing the drugs paclitaxel and sirolimus have been shown to improve long-term, event-free survival compared with bare metal stents. However, restenosis still occurs, and the incidence of stent thrombosis (the formation or presence of a blood clot in a blood vessel), especially after the first year of implantation, is increased with these drug-releasing stents compared with their bare metal counterparts, according to background information in the article. Newer drug-releasing stents are being designed with the goal of enhanced safety, efficacy, or both. Everolimus-releasing stents have shown favorable results in preliminary studies in improving clinical and angiographic outcomes in patients with coronary artery disease.

Gregg W. Stone, MD, of Columbia University Medical Center and the Cardiovascular Research Foundation in New York, and colleagues conducted the SPIRIT III trial to evaluate the everolimus-releasing stent in comparison to the paclitaxel-releasing stent in 1,002 patients with coronary artery disease. Patients were randomized 2:1 to receive the everolimus-releasing stent (n = 669) or the paclitaxel-releasing stent (n = 333). Angiographic follow-up was prespecified at 8 months in 564 patients and completed in 436 patients. Clinical follow-up was performed at 1, 6, 9, and 12 months.

The researchers found that angiographic in-segment late loss (a measure of restenosis) was significantly less in the everolimus-releasing stent group compared with the paclitaxel group. At 9 months, everolimus stents, compared with paclitaxel stents, were noninferior for the outcome of target vessel failure (47 of 657 patients [7.2%] vs. 29 of 321 [9.0%], respectively. Use of the everolimus stent compared with the paclitaxel stent resulted in a 44% reduction (4.6% vs. 8.1%) at 9 months in the composite of major adverse cardiac events (cardiac death, heart attack, or target vessel revascularization [repeat procedure to unblock a blood vessel]), and a 42% reduction in the composite of major adverse cardiac events at 1 year (6.0% vs. 10.3%). This was due to fewer heart attacks and target lesion revascularization procedures.

“This large-scale, prospective, randomized, single-blind, controlled study demonstrates that an everolimus-eluting stent compared with a widely used paclitaxel-eluting stent results in a significant reduction in angiographic in-segment late loss at 8 months, with noninferior 9-month rates of ischemia-driven target vessel failure,” the authors write.

Source: The Journal of the American Medical Association

(View the Daily News Archive)

Survey

Is teleradiology more of a help or a threat to your facility? Help     Threat     We do not use teleradiology in our facility.     View results